iiinova — where your digital self keeps evolving

Kristina Kirschner @krikirschner.bsky.social · 25/06/2025

Happy to have been invited to guest edit this exciting special issue. Check it out!

Kristina Kirschner @krikirschner.bsky.social · 17/06/2025

I’m excited to speak at the #EHASWG Scientific Workshop on Stem Cells and Aging in Barcelona from November 13-15, 2025, and immerse myself in the field of hematopoietic stem cell aging. Submit your abstract for a chance to join me! More info: eha.fyi/SWG_HSC_ft

eha.fyi

EHA-SWG Scientific Workshop on From Aging Hematopoietic Stem Cells to Age-related Diseases: Opportunities for Intervention - The European Hematology Association (EHA)

020

Reposted by Kristina Kirschner

ISEH - International Society for Experimental Hematology @isehsociety.bsky.social · 24/04/2025

This week on #SimplyBlood 🩸 we're highlighting articles in the ExpHem Special Issue: New Culture Methods in Experimental Hematology from guest editor @krikirschner.bsky.social Read the highlights on www.simplyblood.org.

023

Kristina Kirschner @krikirschner.bsky.social · 22/03/2025

Great kick off at the annual Alliance for Healthy Aging Conference hosted by the Mayo Clinic Kogod Centre on Aging Center in Jacksonville Florida with a keynote by @adamsbioaging.bsky.social

010

Reposted by Kristina Kirschner

Richard Sever @richardsever.bsky.social · 11/03/2025

Big news: we are setting up a new non-profit organization to run bioRxiv and medRxiv. It's called openRxiv [no it's not a new preprint server; it's dedicated organization to oversee the servers] openrxiv.org 1/n

openrxiv.org

Homepage - openRxiv

openRxiv is an independent non-profit, the new organizational home for bioRxiv and medRxiv, enabling researchers to instantly share groundbreaking findings with the global scientific community.

552558846

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Our framework enables more accurate prediction of CH's clinical impact, moving us closer to personalized risk assessment and potential intervention strategies.

011

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

MACS120 outperformed traditional measurements (like variant allele frequency) in predicting mortality risk and showed increased correlations with the speed of change in blood markers like lymphocyte and albumin levels.

121

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Considering these factors, we developed MACS120 - a novel metric that combines mutation fitness and acquisition timing to predict maximum clone size a mutation will reach over a lifetime.

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Third, we discovered a strong correlation between mutation timing, or age at time of mutation acquisition (ATMA), and fitness. Higher fitness mutations tend to appear later in life - possibly due to declining quality control mechanisms with age.

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Similarly, mutations can have different fitness effects depending on what other mutations are present in the same clone. For example, ASXL1 mutations have higher fitness when co-occurring with SRSF2 than with TET2.

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Second, we found that clonal coexistence matters! Mutations don't grow in isolation - when multiple clones are present in the same person, they alter each other's overall contribution to the production of blood cells.

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

First, we confirmed gene-specific fitness differences: RNA splicing mutations (like U2AF1, U2AF2) show higher fitness than epigenetic regulator mutations (like DNMT3A, TET2).

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Our key insight: Three factors, mutation fitness (growth advantage), mutation timing, and clonal structure (which mutations occur together) are needed to understand the progression and clinical impact of CH.

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

We integrated data from 713 individuals across 3 longitudinal aging cohorts (2,341 observations total) and developed models to understand the dynamics of CH mutations over time. #CancerResearch #ClonalHematopoiesis

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

Clonal hematopoiesis (CH) is common in aging populations and associated with increased risk of blood cancers and other diseases. But what determines which CH mutations will progress to disease?

111

Kristina Kirschner @krikirschner.bsky.social · 07/03/2025

TUTORIAL: Our new preprint "Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, fitness, and clonal structure" is out @elatorre.bsky.social @edinunilbc.bsky.social @linusschumacher.bsky.social @biologyaging.bsky.social www.biorxiv.org/content/10.1...

biorxiv.org

154